Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    OMP-18R5
Show Display Options
Rank Status Study
1 Active, not recruiting A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
Condition: Solid Tumors
Intervention: Biological: OMP-18R5
2 Recruiting A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
Conditions: Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Vantictumab;   Drug: Nab-Paclitaxel;   Drug: Gemcitabine
3 Recruiting A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
Condition: Solid Tumors
Interventions: Drug: Docetaxel;   Drug: vantictumab
4 Recruiting A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Vantictumab  combined with paclitaxel

Indicates status has not been verified in more than two years